• First ColoSTAT® clinical sale achieved, marking initial revenue
• NHS England laboratory evaluation commenced, opening potential UK and Europe markets
• Manufacturing scale secured via Quansys agreement, supporting future growth

Rhythm Biosciences Ltd (ASX: RHY) delivered a defining quarter in Q3 FY26, marking its transition from development-stage to a commercial diagnostics company. The company generated its first ColoSTAT® clinical revenue, activated national testing infrastructure, secured manufacturing scale, and commenced formal evaluation with NHS England, establishing the key foundations required for sustained commercial growth. The company also announced the conclusion of an exercise and underwriting of RHYO options, strengthening its financial position. Key milestones achieved include the first ColoSTAT® clinical test sale, the commencement of the NHS England laboratory evaluation, the execution of a manufacturing agreement with Quansys Biosciences, and the activation of the 4Cyte national collection network. The company's geneType platform also expanded its commercial footprint through new partnerships in Southeast Asia and Australia, as well as the launch of an enhanced colorectal cancer risk test. The strong and encouraging support from options holders provides additional working capital to support the company's commercial activities and drive sales of ColoSTAT® and geneType in both domestic and international markets.

The company expects to increase ColoSTAT® test volumes through the 4Cyte network and ColoSTAT® Access Program, progress the NHS England laboratory ColoSTAT® analytical evaluation, expand geneType domestic and international commercial partnerships, and advance strategic pathways for ColoSTAT® commercial expansion in Q4 FY26.

Rhythm Biosciences is no longer a development-stage company, but a commercial diagnostics business with two revenue-generating platforms, growing clinical adoption, and a meaningful international pipeline. The company is focused on growing test volumes, deepening clinical engagement, advancing the NHS England evaluation, and expanding its partnership network in the next quarter.